Flagship Ventures Fund V, L.P. 13D and 13G filings for Omega Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-31 5:37 pm Sale | 2024-12-29 | 13D | Omega Therapeutics, Inc. OMGA | Flagship Ventures Fund V, L.P. | 29,225,579 52.800% | -19,852 (-0.07%) | Filing |
| 2023-02-27 5:02 pm Purchase | 2023-02-22 | 13D | Omega Therapeutics, Inc. OMGA | Flagship Ventures Fund V, L.P. | 29,245,431 53.200% | 3,343,162 (+12.91%) | Filing |
| 2021-08-05 6:43 pm Purchase | 2021-08-03 | 13D | Omega Therapeutics, Inc. OMGA | Flagship Ventures Fund V, L.P. | 25,902,269 55.400% | 25,902,269 (New Position) | Filing |